Frontiers in Clinical Drug Research - Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases - diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research - Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The sixth volume of this series features 6 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist. - The failing heart in diabetes with special emphasis on prevention- Flavonoids as prominent anti-diabetic agents- Chemosensor in glucose monitoring, advances and challenges - Synergistic drugs and polyherbal formulations for obesity: current status and future prospectives- Urge for herbal anti-diabetic medicines towards clinical and therapeutic implications- Curcuma longa as a dietary supplement and medication for diabetes mellitus: evidence from experimental studies
Table of Contents
Chapter 1 Clinical and Diagnostic Implications of Glycated Albumin in Diabetes Mellitus: An Update- Introduction
- Non-Enzymatic Glycation
- Non-Enzymatic Glycation in Diabetes
- Human Serum Albumin
- Albumin Structure Upon Glycation
- Biological Properties of Albumin Upon Glycation
- Immunological Properties of Albumin Upon Glycation
- Glycated Albumin as a Diagnosis Marker
- Glycated Albumin Measurements
- Concluding Remarks
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Current Treatments for Type-2 Diabetes Mellitus
- Thiazolidinediones
- Biguanide
- Sulfonylureas
- Meglitinides
- Sglt2 Inhibitors
- Insulin
- Incretin Mimetics
- Complementary Treatments for the Management of T2D
- Natural Products With Anti-Diabetic Properties
- Current and Future Therapies for Type 1 Diabetes
- Stem Cell Therapeutic Approach
- Nanotechnology and Diabetes
- Emerging Technologies for Diabetes Treatment
- Conclusion
- Future Perspectives
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Arbind Kumar Choudhary Background
- Aspartame and Weight Management
- Aspartame and Glucose Intolerance
- Aspartame and Insulin Resistance
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Beáta Erika Nagy, Brigitta Munkácsi and Karolina Eszter Kovács Introduction
- Mental Health and T1Dm
- Quality of Health and Diabetes
- Self-Rated Health in Diabetes
- Illness Representations
- Factors Influencing Adherence
- Adherence in Adolescence
- Factors Influencing Diabetes-Specific Adherence
- The Characteristics of the Illness and the Related Factors
- Intrapersonal Factors
- Interpersonal Factors
- Environmental Factors
- The Purpose of the Study: the Connection Between Mental Health, Adherence and Diabetes
- Sample Characteristics
- Experimental Group: Children Diagnosed With Type-1 Diabetes
- Control Group
- Applied Tools
- Demographic Questions
- The Creation of the Diabetes-Specific Adherence Questionnaire
- The Factor Analysis of the Questionnaire
- Children Depression Inventory (Cdi) [133]
- World Health Organization Well-Being Index (Wbi-5) [134]
- Self-Rated Health (Srh) [135]
- Psychological Mood and Somatic Symptoms [136]
- Satisfaction With Life, Swl-Present (Swl-P) Swl-Future (Swl-F), Cantril-Ladder [137]; Life Evalution Index [138]
- Pediatric Quality of Life Inventory, Pedsql Measurement Model [139, 140]
- Satisfaction With Life Scale (Swls) [141]
- Strengths and Difficulties Questionnaire (Sdq) [142]
- Research Questions and Hypotheses
- Results
- The General Description of Adherence
- The Relationship Between Adherence and the Indexes of Mental Health
- Psychological Factors Influencing Adherence
- Summary
- Sociodemographic Factors Influencing Adherence
- Psychological Factors Influencing Adherence
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Omar M. Abdelfattah, Ahmed Sayed, Anas Al-Refaei, Jasmin Abdeldayem, Khaled Moustafa, Nicholas Elias and Yehia Saleh Introduction
- Sodium/Glucose Cotransporter-2 Inhibitors (Sglt2I)
- History, Mechanisms, and Pleiotropic Effects of Sglt2I
- Pivotal Clinical Trials Involving Slgt2I
- Dual Sglt1/2 Inhibitors: the Next Step in the Evolution of Sglt2I?
- Incretins
- History of Incretins and Their Mechanisms of Action
- Safety and Efficacy of Ddp-4I
- Trials Evaluating the Safety and Efficacy of Glp-1Ras
- Summary and Synthesis of the Literature on Incretins
- Insulin
- A Historical Overview of the Discovery of Insulin
- The Role of Glycemic Control in Outcome-Optimization and a Discussion of Trials on Recent Insulin Formulations
- Alpha-Glucosidase Inhibitors
- Thiazolidinediones
- Comparison of the Different Novel Modalities and Critical Gaps in the Literature
- Lipid-Lowering Therapies Statins
- Historical Context and Foundational Trials (Pre-2010)
- Contemporary Analyses and Trials (2010 and Onwards)
- Pcsk9 Inhibitors
- Rationale and Initial Discoveries
- Trials Demonstrating Ldl-Lowering Efficacy
- Evidence of Clinical Efficacy and Reduction of Hard Outcomes
- Omega-3 Fatty Acids
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Mohamed E. Elrggal, Ahmed Elkeraie, Sol Carriazo, Hany Sawaf, Si Yuan Khor, Yasmine Elkeraie, Issa Haddad, Khaled Moustafa and Mohamed Hassanein Introduction
- Epidemiology and Genetic Aspects Shared in Diabesity and Kidney Diseases
- Pathophysiologic Mechanisms Cross-Linking Diabesity and Kidney Diseases
- Obesity
- Diabetes
- Diabesity
- Non-Pharmacological Management
- A. Exercise
- B. Dietary Therapy
- C. Behavioral Modifications
- Pharmacological Treatment for the Management of Diabesity and Related Kidney Disease
- Anti-Diabetic Medications
- Glp-1 Receptor Agonists
- Liraglutide
- Dulaglutide
- Semaglutide
- Sglt2 Inhibitors
- Metformin
- Anti-Obesity Medications
- Orlistat
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Surgical Options to Control Diabesity and Kidney Disease
- Future Pipeline Treatment
- Tirzepatide
- Cotadutide
- Amylin Analogs
- Leucine/Metformin/Sildenafil Combination
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Subject Index
